头颈癌放疗患者继续吸烟的影响:系统综述与Meta分析
该系统综述与Meta分析检索1990年1月至2018年8月14日的多个数据库,纳入24篇文献共6332例以放疗为主的患者,发现继续吸烟与头颈癌患者死亡风险约为不吸烟者的两倍及局部区域失败风险升高相关,定性分析提示继续吸烟可能增加晚期而非急性毒性发生率。
要点
- 继续吸烟与头颈癌患者死亡风险升高相关(RR=1.85,95%CI 1.55-2.21,p<0.0001,I²=43%)。
- 继续吸烟与局部区域失败风险升高相关(RR=2.24,95%CI 1.42-3.52,p=0.0005,I²=64%)。
- 定性分析提示继续吸烟可能增加晚期毒性发生率,但未增加急性毒性。
核心结论
- 本综述提供证据表明,继续吸烟与头颈癌患者较低的总生存和局部区域控制以及较高的晚期毒性发生率相关。
- 因此,临床医生应强烈鼓励所有头颈癌患者戒烟。
研究设计与样本
- 系统综述与Meta分析,检索1990年1月至2018年8月14日PubMed、MEDLINE(Ovid)、Embase、Scopus、The Cochrane Library、CINAHL和AUSThealth的文章。
- 纳入标准为多数患者接受放疗且吸烟者定义为在放疗期间或放疗后继续吸烟者。
- 初始检索识别2217项研究,最终纳入24篇文章共6332例患者。
- 数据提取和偏倚风险评估由三名独立共同作者使用原始研究的汇总数据进行。
- 对总生存和局部区域控制采用随机效应模型进行Meta分析;由于可用文章数量有限,对毒性和生活质量进行定性合成。
主要发现
- 继续吸烟与头颈癌患者死亡风险约为不吸烟者的两倍相关(RR=1.85,95%CI 1.55-2.21,p<0.0001,I²=43%)。
- 继续吸烟与头颈癌患者局部区域失败风险升高超过两倍相关(RR=2.24,95%CI 1.42-3.52,p=0.0005,I²=64%)。
- 定性合成提示继续吸烟可能增加晚期毒性发生率,但不增加急性毒性发生率。
关键数值与推荐
- 继续吸烟与死亡风险的RR=1.85(95%CI 1.55-2.21,p<0.0001,I²=43%)。
- 继续吸烟与局部区域失败的RR=2.24(95%CI 1.42-3.52,p=0.0005,I²=64%)。
临床怎么用
- 作者认为,临床医生应强烈鼓励所有头颈癌患者戒烟。
局限性
- 毒性和生活质量仅进行定性合成,因为只有有限数量的文章可用。
- 总生存分析的异质性I²=43%。
- 局部区域控制分析的异质性I²=64%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To determine the effects of continued smoking in head and neck cancer (HNC) patients undergoing radiotherapy on overall survival (OS), locoregional control (LRC), quality of life (QoL) and acute and late toxicities. METHODS: Articles from January 1990 to August 14, 2018 were searched in PubMed, MEDLINE (Ovid), Embase, Scopus, The Cochrane Library, CINAHL and AUSThealth. Articles were included if majority of patients were treated with radiotherapy and smokers were defined as those who continued to smoke during or after radiotherapy. Data extraction and risk of bias assessment was performed by three independent co-authors using summary data of original studies. A meta-analysis using a random effects model was conducted for OS and LRC. In addition, a qualitative synthesis was performed for toxicities and quality of life as only a limited number of articles were available. RESULTS: The initial search identified 2217 studies, with 24 articles comprising 6332 patients eligible for inclusion. Analysis demonstrated that continued smoking was associated with approximately two times the risk of mortality (RR = 1.85, 95% CI 1.55-2.21, p < 0.0001, I2 = 43%) in HNC patients. Similarly, the risk of locoregional failure was more than two times greater in HNC patients who continued smoking (RR = 2.24, CI 1.42-3.52, p = 0.0005, I2 = 64%). The qualitative synthesis indicates that continued smoking may contribute to an elevated incidence of late but not acute toxicities. CONCLUSIONS: This review provides evidence that continued smoking is associated with a lower OS and LRC and a higher incidence of late toxicities. Therefore, clinicians should strongly encourage smoking cessation amongst all head and neck cancer patients.
引用
- Smith J, Nastasi D, Tso R, et al. The effects of continued smoking in head and neck cancer patients treated with radiotherapy: A systematic review and meta-analysis. Radiother Oncol. 2019. PMID: 31015170. doi:10.1016/j.radonc.2019.02.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。